Metastatic melanoma treatment gets Breakthrough Therapy Designation
Breakthrough Therapy Designation has been granted for investigational agent bempegaldesleukin…
Breakthrough Therapy Designation has been granted for investigational agent bempegaldesleukin in combination with nivolumab.